Susanna Mandruzzato

Padova, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer
Published: January 11, 2026

Editorial: Roles of macrophages and monocytes in resistance to immunotherapy in cancers.

Editorial: Roles of macrophages and monocytes in resistance to immunotherapy in cancers.

Journal: Frontiers in immunology
Published: January 09, 2026

ZnPPIX-Loaded Nanoemulsions Reprogram Immunosuppressive Macrophages in Vitro: A Potential Strategy for Glioblastoma Microenvironment Modulation.

ZnPPIX-Loaded Nanoemulsions Reprogram Immunosuppressive Macrophages in Vitro: A Potential Strategy for Glioblastoma Microenvironment Modulation.

Journal: International journal of nanomedicine
Published: June 06, 2025

Drug-loaded nanoparticles induce immunogenic cell death and efficiently target cells from glioblastoma patients.

Drug-loaded nanoparticles induce immunogenic cell death and efficiently target cells from glioblastoma patients.

Journal: Nanomedicine (London, England)
Published: May 06, 2025

Transcriptomic profiling of cytomegalovirus infection in cardiac transplantation: proof-of-concept for a new strategy in tissue markers application.

Transcriptomic profiling of cytomegalovirus infection in cardiac transplantation: proof-of-concept for a new strategy in tissue markers application.

Journal: Frontiers in immunology
Published: February 21, 2025

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Journal: Trials
Published: February 17, 2025

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.

Journal: The oncologist
Published: August 24, 2023

The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.

The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.

Journal: Frontiers in immunology
Published: June 08, 2023

Sodium fluorescein uptake by the tumor microenvironment in human gliomas and brain metastases.

Sodium fluorescein uptake by the tumor microenvironment in human gliomas and brain metastases.

Journal: Journal of neurosurgery
Published: April 24, 2023

Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.

Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.

Journal: Science translational medicine
Published: March 15, 2023

Editorial: Novel roles for tumor-associated neutrophils.

Editorial: Novel roles for tumor-associated neutrophils.

Journal: Frontiers in immunology
Published: July 27, 2022

The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients.

The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients.

Journal: International journal of cancer
Published: May 23, 2022
Showing 1-12 of 50

Last Updated: 09/26/2026